By Fineline Cube 
French pharmaceutical major Sanofi (NASDAQ: SNY) is set to make a USD 25 million investment in China-based Adagene Inc. (NASDAQ: ADAG), further solidifying their collaboration under the SAFEbody framework. This investment will initiate the third development program within their partnership.
Advancing Clinical Trials
The funds will primarily be used to advance the research and development of muzastotug (ADG126), an anti-CTLA-4 SAFEbody, with a particular emphasis on Phase II clinical trials for microsatellite stable colorectal cancer (MSS CRC).
Collaboration Details
Adagene will supply Sanofi with muzastotug for a Phase I/II study aimed at evaluating the safety, efficacy, pharmacokinetics, and biomarker data when combined with other anticancer therapies. This study will involve over 100 patients with advanced solid tumors. Despite the collaboration, Adagene retains worldwide commercial rights to muzastotug.-Fineline Info & Tech